0QNV Stock Chart & Stats
$0.02
>-$0.01(-8.00%)
―
--
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)74.17K
Market Cap
CHF2.64M
Enterprise Value$3.74
Total Cash (Recent Filing)CHF937.50K
Total Debt (Recent Filing)CHF102.27K
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding218,654,500
10 Day Avg. Volume112,800
30 Day Avg. Volume74,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Neurological PipelineAddex has generated reproducible preclinical efficacy across species for its GABAB PAM cough program, alongside a reported safety margin and no observed tolerance. This supports a differentiated development opportunity and provides a credible scientific basis for future partnering or clinical advancement.
Partnership Milestone And Royalty PotentialThe Indivior collaboration gives Addex access to substantial contingent milestone and royalty economics without requiring the company to independently fund every development stage. Partner-led progress could create non-linear revenue potential and validate the underlying discovery platform over time.
Low Financial LeverageMinimal debt reduces interest burden and balance-sheet pressure compared with a highly leveraged development company. This provides greater flexibility in negotiating partnerships, allocating scarce capital to priority programs, and managing funding needs without substantial debt-service obligations.
Bears Say
Limited Cash RunwayThe available cash runway is insufficient to advance unpartnered programs into the clinic, making additional financing or partnering necessary for key development steps. This can delay catalysts, weaken negotiating leverage, and expose shareholders to dilution or execution risk.
Persistent Losses And Cash BurnContracting revenue and deeply negative profitability show that Addex has not yet built a self-funding operating model. Continued operating and free-cash-flow deficits require external capital or partner receipts, limiting the company’s ability to sustain development independently.
Dependence On External Funding And PartnersSeveral important programs cannot progress on their current funding base, so scientific promise must be converted through financing or third-party agreements. The absence of guaranteed commitments raises the risk that development timelines, program scope, or strategic control may change.
Addex Therapeutics News
0QNV FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest share price was $0.02 and its highest was $0.08 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF2.64M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 52 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Jun 25, 2026. The company reported -$0.01 earnings per share for the quarter.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in GB:0QNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.